

PROSPECTUS

RENOVO | RX

6,960,864 Shares of Common Stock
951,500 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrant
7,912,364 Shares of Common Stock Issuable Upon Exercise of Series A Warrants
3,956,182 Shares of Common Stock Issuable Upon Exercise of Series B Warrants
701,243 Shares of Common Stock Issuable Upon Exercise of Placement Agent Warrants

This prospectus relates to the resale by the selling stockholders named herein, including their transferees, assigns, pledgees or donees, or their respective successors, of up to (i) 6,960,864 shares (the “Shares”) of our common stock, par value \$0.0001 per share (which we refer to as our common stock), (ii) 951,500 shares (the “PFW Shares”) issuable upon exercise of a pre-funded warrant held by one of the selling stockholders, (iii) 7,912,364 shares (the “Series A Warrant Shares”) of our common stock issuable upon the exercise of Series A warrants (the “Series A Warrants”) held by certain of the selling stockholders, (iv) 3,956,182 shares (the “Series B Warrant Shares”) of our common stock issuable upon the exercise of Series B warrants (the “Series B Warrants”) held by certain of the selling stockholders and (v) 701,243 shares (the “PA Warrant Shares”) of our common stock issuable upon the exercise of placement agent warrants (the “PA Warrants”) held by certain of the selling stockholders. The Shares, Pre-Funded Warrant, Series A Warrants, Series B Warrants and PA Warrants were issued by us in a private placement which closed on April 11, 2024 (the “April 2024 Private Placement”). The selling stockholders listed herein were the investors in the April 2024 Private Placement or are persons associated with the placement agent for the April 2024 Private Placement. For information about the selling stockholders, see “Selling Stockholders.”

We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of common stock by the selling stockholder, although we may receive funds upon the future the exercise of Series A Warrants, Series B Warrants and PA Warrants held by certain of the selling stockholders, if and when exercised for cash. The selling stockholders may sell Shares, Series A Warrant Shares, Series B Warrant Shares and PA Warrant Shares (which we sometimes refer to herein collectively as the Selling Stockholder Shares) from time to time in the principal markets on which the common stock is quoted at the prevailing market price, at prices related to prevailing market prices or in negotiated transactions. The selling stockholders may sell the Selling Stockholder Shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling stockholders, the purchasers of the Selling Stockholder Shares, or both. We are registering the offer and sale of the Selling Stockholder Shares pursuant to certain registration rights granted to the selling stockholders. The timing and amount of any sale of Selling Stockholder Shares is within the sole discretion of the selling stockholders. We do not know when or in what amount of Selling Stockholder Shares the selling stockholders may offer for sale. We will pay the expenses of registering the Selling Stockholder Shares, including legal and accounting fees. All selling and other expenses incurred by the selling stockholders will be borne by the selling stockholders. See “Plan of Distribution” for additional information.

Our common stock is listed on The Nasdaq Capital Market under the symbol “RNXT.” On May 8, 2024, the last reported sale price of our common stock on The Nasdaq Capital Market was \$1.37 per share.

The purchase of the common stock offered through this prospectus is speculative and involves a high degree of risk. You should carefully consider the risk factors beginning on page 4 of this prospectus before purchasing any of the securities offered by this prospectus.

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.

Neither the Securities and Exchange Commission (“SEC”) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is May 10, 2024.

TABLE OF CONTENTS

	<u>Page</u>
About This Prospectus	ii
Cautionary Note Regarding Forward-Looking Statements	iii
Prospectus Summary	1
The Offering	3
Risk Factors	4
Use of Proceeds	5
Selling Stockholders	6
Plan of Distribution	11
Legal Matters	13
Experts	13
Where You Can Find More Information	13
Incorporation of Certain Information by Reference	13

ABOUT THIS PROSPECTUS

The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus, in any prospectus supplement or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information.

We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus and any accompanying prospectus supplement or any related free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement or any related free writing prospectus. This prospectus and any accompanying prospectus supplement and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any accompanying prospectus supplement and any related free writing prospectus, if any, constitute

an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any accompanying prospectus supplement and any related free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement and any related free writing prospectus is delivered or securities are sold on a later date.

We have not done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourself about and to observe any restrictions relating as to this offering and the distribution of this prospectus and any such free writing prospectus outside the United States.

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

We own or have rights to use a number of registered and common law trademarks, service marks and/or trade names in connection with our business in the United States and/or in certain foreign jurisdictions. Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the ® and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies' trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. We have trademarks for the names RENOVORX, RENOVOGEM, RENOVOCATH, RENOVOTAMP and DELIVERING THERAPY WHERE IT MATTERS. We have trademarks pending for TAMP and RENOVOGEM.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus, any accompanying prospectus supplement and the information incorporated by reference herein contain forward-looking statements. All statements other than statements of historical facts contained in this prospectus and the information incorporated by reference herein, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements about:

- our ongoing need for capital, and the sufficiency of our existing cash, cash equivalents, and investments to fund our future operating expenses and capital expenditure requirements;
- our estimates regarding expenses, future potential revenue, anticipated capital requirements to fund our future operating expenses, and our need for additional financing;
- our financial performance and other results of operations;
- our anticipated use of our existing cash, cash equivalents, and investments;
- our estimates of the number of patients in the United States who suffer from the diseases we target and our estimates regarding the size of other potential market opportunities and our ability to successfully realize these opportunities;
- the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and to otherwise meet their primary and secondary endpoints;
- the enrollment timing and projections for our clinical trials and focus on our current and future clinical trials, and the timing of reporting of interim or final data from those trials;
- our expectations relating to the timing of the provision of updates on, data readouts for, and completion of our clinical trials
- our continued reliance on third parties to conduct clinical trials of our product candidates, and for the manufacture of our product candidates;
- the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;
- our ability to advance product candidates into and successfully complete clinical trials;
- our ability to further develop and expand our therapy delivery platform, both to use different chemotherapeutic agents and to include new indications;
- our ability to obtain and maintain regulatory approval of our product candidates and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such as orphan drug designation, for our product candidates for various diseases;
- existing regulations and regulatory developments in the United States and other jurisdictions;

- our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and our potential and ability to successfully commercialize our product candidates and generate revenue;
- the development, negotiation, documentation and implementation of actual or potential strategic plans for our business and product candidates, including licenses, joint ventures and other commercial collaborations;
- the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with relevant and complementary expertise;

- the pre-clinical and clinical development, and commercialization, of competing therapies that are or may become available;
- future developments related to our industry, including developments by our competitors;
- our plans relating to the further development and manufacturing of our product candidates, including for additional indications which we may pursue;
- our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;
- the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform and product candidates;
- our potential and ability to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved;
- our ability to retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel; and
- our expectations regarding the impact of geopolitical events on our business, including pandemics, wars, and political, economic or capital market instability.

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this prospectus, each accompanying prospectus supplement, and the information incorporated by reference herein and therein. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

PROSPECTUS SUMMARY

The following summary highlights information contained elsewhere in this prospectus. It does not contain all of the information you need to consider in making your investment decision. Before making an investment decision, you should read this entire prospectus carefully and you should consider, among other things, the matters set forth under “Risk Factors” and our financial statements and related notes thereto appearing elsewhere in this prospectus.

In this prospectus, except as otherwise indicated, “RenovoRx,” the “Company,” “we,” “our,” and “us” refer to RenovoRx, Inc., a Delaware corporation.

Company Overview

We are a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. Our proprietary **Trans-Arterial Micro-Perfusion (TAMP™)** therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic (intravenous (known as IV) therapy). Our novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy.

Our novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Phase III lead product candidate, **RenovoGem™**, an oncology drug-device combination product, is being investigated under a U.S. Investigational New Drug Application (IND) that is regulated by U.S. Food and Drug Administration (or FDA) under the 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA.) We also plan to evaluate RenovoGem as a potential therapy in bile duct cancer with other potential pipeline indication opportunities to follow including non-small cell lung cancer, uterine tumors, glioblastoma, and sarcoma. RenovoGem received Orphan Drug Designation for pancreatic cancer and bile duct cancer which provides 7 years of market exclusivity upon NDA approval.

We have completed our RR1 Phase I/II and RR2 observational registry studies, with 20 and 25 patients respectively, in LAPC. These studies demonstrated a median Overall Survival (OS) of 27.9 months in LAPC patients pre-treated with radiation followed by treatment with RenovoGem. Based on previous large randomized clinical trials, the expected survival of LAPC patients is 12 to 15 months in patients receiving only IV systemic chemotherapy or IV chemotherapy plus radiation (which are both considered standard of care). Unlike the randomized trials that established these standard of care results, our RR1 and RR2 clinical trials did not prospectively control the standard of care therapy received prior to administration of RenovoGem. Based on an FDA safety review of our Phase I/II study, the FDA allowed us to proceed to evaluate RenovoGem within our Phase III registrational clinical trial.

Our Phase III clinical trial of RenovoGem for the treatment of LAPC is called **TIGeR-PaC**. This trial is an ongoing randomized multi-center study using TAMP to evaluate RenovoGem. The study is evaluating trans-arterial delivery, a form of intra-arterial (IA) administration, of an FDA-approved chemotherapy, gemcitabine, to treat LAPC following stereotactic body radiation therapy (SBRT). The study is comparing treatment of an FDA-approved cancer drug, gemcitabine, with TAMP versus systemic IV administration of gemcitabine and nab-paclitaxel.

Our protocol for TIGeR-PaC involves systemic chemotherapy and only SBRT during the induction phase of the study (prior to randomization). Patients receiving SBRT during the induction phase are required to complete 5 treatments, over 5 consecutive days, and do not receive oral chemotherapy vs. previously utilized intensity-modulated radiation therapy (IMRT) where patients must complete 25 radiation treatments in combination with oral chemotherapy during the induction phase of the study, which takes between 35 and 56 days to complete. In December 2021, we amended our protocol and statistical analysis plan for TIGeR-PaC (the “Modified SAP”) to (i) analyze only patients receiving SBRT during the induction phase, (ii) include a second interim analysis, (iii) change the total number of patients randomized in the study to 114 with a total of 86 deaths from SBRT patients, and (iv) repower the study from 90% to 80%, which is commonly used in clinical trials. We believe this design will shorten the timeframe needed to complete the study and also significantly decrease our costs. We have not discussed the protocol amendment or the Modified SAP with the FDA, and we cannot provide any assurance that the FDA will agree with these modifications, but these modifications have been submitted to the FDA

The first interim analysis in the TIGeR-PaC study at the 26th event of the specified events (deaths), was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study's primary endpoint is a 6-month OS (Overall Survival) benefit with secondary endpoints including reduced side effects versus standard of care. The data was first presented at the 2023 American Association for Cancer Research Annual Meeting in April 2023 and then as a Late Breaker Oral Presentation with additional secondary endpoint data at the 2023 European Society of Medical Oncology World Congress on Gastrointestinal Cancer in June 2023. The second interim analysis for this study will be triggered by the 52nd event, which is estimated to occur in late 2024. The second interim data read out would follow thereafter, with the timing for such read out depending on customary factors such as time needed for analysis.

Our TAMP therapy platform is focused on optimizing drug concentration in solid tumors using approved small molecule chemotherapeutics. Our platform enables physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach solid tumors in chemotherapy. Specifically, our patented approach allows physicians to combine, on the one hand, pre-treatment of the local blood vessels and tissue with standard-of-care radiation therapy to decrease chemotherapy washout and, on the other hand, local delivery via our patented **RenovoCath** delivery system which utilizes pressure to force small molecule chemotherapy into the tumor tissue. We believe there are many advantages to our TAMP therapy platform, including:

- *Application of Approved Small Molecule Chemotherapeutic Agents:* We use approved small molecule chemotherapeutic agents, such as gemcitabine, with well-known safety and efficacy profiles.
- *Targeted Approach:* In a preclinical study using our therapy platform, we demonstrated up to 100 times higher local drug concentration compared to systemic chemotherapy. We believe our TAMP therapy platform allows for a targeted approach that can decrease systemic exposure and improve patient outcomes.
- *Delivery Method Independent of Tumor Vascularity:* Our therapy platform is designed to deliver small molecule chemotherapeutic agents to solid tumors resistant to systemic chemotherapy due to lack of tumor feeder blood vessels. If approved, our product candidates have the potential to treat tumors that are not directly supported by blood vessels.
- *Broad Application for Solid Tumor Indications:* Our therapy platform is not restricted to a single small molecule chemotherapeutic agent or solid tumor type. As such, it may be applied for use in additional solid tumor indications, including in solid tumors without identifiable tumor feeder blood vessels.

In a further validation of our TAMP platform, in July 2023, we announced a collaboration with Imugene(ASX: IMU) to explore expansion of our TAMP product pipeline with Imugene's CF33 oncolytic virus therapy for the treatment of difficult-to-access tumors. We are constantly in discussions regarding similar collaborations and potentially out-licenses of RenovoGem as we gear up for the New Drug Application filing (assuming we meet our study endpoints) and commercialization of RenovoGem (if approved by FDA) as well as other collaborations with our TAMP platform.

Corporate Information

We were incorporated in the State of Delaware on December 17, 2012. Our principal executive offices are located at 4546 El Camino Real, Suite B1, Los Altos, CA 94022. Our telephone number is (650) 284-4433. Our website address is <https://renovorx.com>. Information contained in our website does not constitute any part of, and is not incorporated into, this prospectus.

THE OFFERING

Common Stock to be offered:	6,960,864 Shares, 951,500 PFW Shares, 7,912,364 Series A Warrant Shares, 3,956,182 Series B Warrant Shares and 701,243 PA Warrant Shares held or acquirable by the selling stockholders.
Terms of the Offering:	The selling stockholders will determine when and how to sell the Selling Stockholder Shares offered in this prospectus, as described in "Plan of Distribution."
Use of Proceeds:	We will not receive any proceeds from the sale of Selling Stockholder Shares in this offering. However, we may receive proceeds from the exercise of the Series A Warrants, Series B Warrants and PA Warrants by the selling stockholders to the extent they are exercised for cash. In the event we receive proceeds from the cash exercise of the Series A Warrants, Series B Warrants and the PA Warrants, we intend to use the aggregate net proceeds from such exercise for general corporate purposes, including working capital. See the sections titled "Use of Proceeds" and "Selling Stockholders" for additional information.
Listing and Symbols:	Our common stock is listed on The Nasdaq Capital Market under the symbol "RNXT".
Risk Factors:	<i>Investing in our securities is speculative and involves substantial risks.</i> You should read the "Risk Factors" section of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of factors to consider before deciding to purchase our securities.

Shares of our common stock that may be offered under this prospectus will be fully paid and non-assessable. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the selling stockholders for offer and resale, we are referring to the Shares that have been issued to the selling stockholders and the PFW Shares, the Series A Warrant Shares, Series B Warrants and PA Warrant Shares issuable upon exercise of Warrants and PA Warrants issued in the January 2024 Private Placement. When we refer to the selling stockholders in this prospectus, we are referring to the selling stockholders identified in this prospectus and, as applicable, their permitted transferees or other successors-in-interest that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which this prospectus is a part.

RISK FACTORS

Investing in our securities is speculative and involves a high degree of risk. Before making a decision to invest in our securities, in addition to carefully considering the Risk Factors noted below and the other information contained in this prospectus and incorporated by reference herein, you should carefully consider the risks described under the caption "Risk Factors" contained in our Annual Report on Form 10-K for our fiscal year ended December 31, 2023 and in our other filings with the Securities and Exchange Commission, as well as any amendments thereto, which are incorporated by reference into this prospectus in their entirety. See "Where You Can Find More Information" and "Incorporation of Certain Information by Reference."

Risks Relating to this Offering

If you purchase the common stock being offered in this offering, you may experience immediate dilution as a result of this offering.

Since the price per share of our common stock being offered may be substantially higher than the net tangible book value per share of our common stock, you may suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering.

You may experience future dilution as a result of future equity offerings.

In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock that could result in further dilution to the investor purchasing our common stock in this offering or result in downward pressure on the price of our common stock. We may sell shares of our common stock or other securities in any other offering at prices that are higher or lower than the prices paid by the investor in this offering, and the investor purchasing shares or other securities in the future could have rights superior to existing stockholders. Moreover, to the extent that we issue options or warrants to purchase, or securities convertible into or exchangeable for, shares of our common stock in the future and those options, warrants or other securities are exercised, converted or exchanged, stockholders may experience further dilution.

The trading price of our common stock has been, and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control.

Our stock price is volatile. During the period from May 1, 2023 to May 1, 2024, the closing price of our common stock ranged from a high of \$3.12 per share to a low of \$0.60 per share. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the public offering price and you may lose some or all of your investment.

We issued a large number of shares of common stock and warrants to purchase common stock in connection with our 2024 financing activities. Substantial future sales of such shares of our common stock could cause the market price of our common stock to decline or have other adverse effects on our company.

In connection with our private placement financing activities in the first few months of 2024, we issued a large number of shares and warrants to purchase common stock. We are obligated to register such shares and shares underlying warrants (totaling an aggregate of approximately 13 million shares of common stock and approximately 20 million shares of common stock underlying warrants) for public resale. While registered, these shares will be freely tradable. Sales of a substantial number of these shares in the public market, or the perception that these sales might occur, could depress the market price of our common stock or cause such market price to decline significantly. Such sales or the perception that such sales might occur could also impair our ability to raise capital through the sale of additional equity securities. We are unable to predict with any certainty the effect that such sales, or the perception that such sales may occur, may have on the prevailing market price of our shares or other adverse impacts that this situation could have on our company.

Risks Relating to Our Business

We will need to raise substantial additional capital to develop and commercialize RenovoGem, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts. If we do not obtain adequate and timely funding, we may not be able to continue as a going concern.

We had cash, cash equivalents and short-term marketable securities of \$1.2 million as of December 31, 2023. Due to our recurring operating losses and the expectation that we will continue to incur net losses in the future, we have recently raised, and will be required in the future to raise, additional capital to complete the development and commercialization of our product candidates. We have historically financed our operations primarily through private sales of our equity, debt financing and the sale of common stock and warrants in our initial public offering, or IPO. To raise additional capital, we may seek to sell additional equity and/or debt securities, obtain a credit facility or other loan or enter into collaborations, licenses or other similar arrangements, which we may not be able to do on favorable terms, or at all. For example, we have filed an omnibus shelf registration statement on Form S-3 that provides for aggregate offerings of up to \$50.0 million of our securities subject to various limitations, including limited sales in any twelve-month period while we are subject to the “baby-shelf” rules. Our ability to obtain additional financing will be subject to a number of factors, including market conditions, fluctuations in interest rates, our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of our product candidates, restrict or cease our operations or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional capital on acceptable terms, or at all, would result in a material and adverse impact on our operations. As a result, there is substantial doubt about our ability to continue as a going concern.

Our financial statements as of December 31, 2023 have been prepared on a going concern basis and do not include any adjustments that may result from the outcome of this uncertainty. If we fail to raise additional working capital, or do so on commercially unfavorable terms, it would materially and adversely affect our business, prospects, financial condition and results of operations, and we may be unable to continue as a going concern. As a result, there is substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, if at all. If we are unable to continue as a going concern, we might have to liquidate our assets and the value we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements, and our shareholders may lose their entire investment in our common stock.

USE OF PROCEEDS

We will not receive any proceeds from the sale of the Selling Stockholder Shares by the selling stockholders. However, we may receive proceeds from the exercise of the Series A Warrants, Series B Warrants and PA Warrants by the selling stockholders to the extent they are exercised for cash. We estimate that the maximum proceeds that we may receive from the exercise of the Warrants and PA Warrants, assuming all the Warrants are exercised for cash at their applicable exercise prices of either \$1.22 or \$1.69, will be approximately \$16.2 million. We do not know, however, whether any of the Series A Warrants, Series B Warrants or PA Warrants will be exercised or, if any of such warrants are exercised, when they will be exercised. It is possible that the Series A Warrants, Series B Warrants and PA Warrants will expire and never be exercised. There are circumstances under which the Series A Warrants, Series B Warrants and the PA Warrants may be exercised on a cashless basis. In these circumstances, even if such warrants are exercised, we may not receive any proceeds, or the proceeds that we do receive may be significantly less than what we might expect.

We will retain broad discretion over the use of the net proceeds to us from the exercise of the Series A Warrants, Series B Warrants and the PA Warrants. Unless otherwise provided in the applicable prospectus supplement, we currently expect to use the aggregate net proceeds from the exercise of the Series A Warrants, Series B Warrants and PA Warrants for general corporate purposes, including working capital. We may also use a portion of the net proceeds to acquire, license or invest in complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction. The expected use of net proceeds from the exercise of the Series A Warrants, Series B Warrants and the PA Warrants represents our current intentions based on our present plans and business conditions. We cannot specify with certainty all of the particular uses for the net proceeds to be received from the exercise of the Series A Warrants, Series B Warrants and PA Warrants. Pending these uses, we plan to invest the net proceeds of this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. The actual allocation of proceeds realized from the exercise of the Series A Warrants, Series B Warrants and the PA Warrants will depend upon the amount and timing of such exercises, our operating revenues and cash position at such time and our working capital requirements.

The selling stockholders will pay any expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by

the selling stockholders in disposing of their shares of common stock. We will bear all other costs, fees and expenses incurred in effecting the registration of the Selling Stockholder Shares covered by this prospectus, including, without limitation, all registration fees and fees and expenses of our counsel and our accountants.

SELLING STOCKHOLDERS

The shares of common stock being offered by the selling stockholders listed below were issued in, or are underlying the Series A Warrants, Series B Warrants and PA Warrants issued in connection with, the April 2024 Private Placement. Other than the relationships as purchasers under the Subscription Agreements (as defined below) and as otherwise described herein, to our knowledge, no material relationships exist between any of the selling stockholders and us nor have any such material relationships existed within the past three years.

As used herein, the term “selling stockholders” means the selling stockholders listed below and such holders’ donees, pledgees, transferees, or other successors-in-interest selling shares of common stock or warrant shares received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer.

Summary of April 2024 Private Placement

On April 4, 2024, we entered into a series of subscription agreements (the “Subscription Agreements”), in connection with the April 2024 Private Placement to 172 accredited investors (who are among the selling stockholders hereunder), which private placement was also closed on April 11, 2024. In connection with the April 2024 Private Placement, we raised aggregate gross proceeds of approximately \$11.1 million.

In connection with the April 2024 Private Placement, we sold to the selling stockholder who were investors in the placement an aggregate of (i) 6,960,864 shares (the “Shares”) of our common stock, (ii) a Pre-Funded Warrant to one investor to purchase 951,500 PFW Shares, (iii) Series A Warrants to purchase an aggregate of 7,912,364 shares of common stock, and (iv) Series B Warrants to purchase an aggregate of 3,956,182 Series B Warrant Shares.

Investors paid a purchase price of \$1.22 for each Share and related Series A Warrant and Series B Warrant. The exercise price of the Series A Warrants and the Series B Warrants is also \$1.22 per share.

The Pre-Funded Warrant is exercisable until the entire Pre-Funded Warrant is exercised at an exercise price of \$0.0001 per PFW Share, subject to customary adjustments thereunder. The Pre-Funded Warrant is immediately exercisable upon issuance, subject to certain beneficial ownership limitations.

The Series A Warrants are exercisable at any time and from time to time through and including the fifth anniversary of the issuance date, and each Series A Warrant will entitle the holder to purchase Warrant Shares for an exercise price equal to \$1.22 per share.

The Series B Warrants are exercisable at any time and from time to time through and including the second anniversary of the issuance date and will entitle the holder to purchase Warrant Shares at an exercise price equal to \$1.22 per share. After six months from the closing date of April 2024 Private Placement, the Series B Warrants are callable by us for \$0.0001 per Series B Warrant, subject to (i) our common stock trading for seven consecutive trading days (with a trading volume of at least 75,000 shares on each day) at a price that is greater than the exercise price of the Series B Warrants by at least 150% of such exercise price and (ii) the Series B Warrant Shares being registered for public resale pursuant to an effective registration statement. Holders of Series B Warrants will be afforded a period of five (5) trading days to exercise their Series B Warrants if the call right is exercised by the Company.

The exercise price and the number of shares of common stock issuable upon exercise of the Series A Warrants and Series B Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock, and also upon any distributions of assets, including cash, stock or other property to our stockholders.

Pursuant to the Subscription Agreements, we agreed to use our commercially reasonable efforts to file a registration statement for the resale of the Shares and the Investor Warrant Shares, within 15 days after the closing of the April 2024 Private Placement and to cause the SEC to declare such registration statement effective as promptly as possible thereafter. We have filed the registration statement of which this prospectus is a part to satisfy this obligation.

Newbridge Securities Corporation (the “Placement Agent”) acted as the placement agent for the April 2024 Private Placement. For its services rendered, we paid selling commissions of 12% of gross offering proceeds from the sale of the Shares, Series A Warrants and Series B Warrants in the April 2024 Private Placement; *provided, however*, that selling commissions of 3% of gross offering proceeds were paid with respect to all subscriptions received from investors who were introduced by us. Total selling commissions paid by us to the Placement Agent were \$1,280,937.39. We also paid the Placement Agent \$50,000 for its expenses. In addition, as additional compensation, we issued PA Warrants to the Placement Agent and its designees to purchase an aggregate of up to 701,243 PA Warrant Shares at an exercise price of \$1.69 per share and also agreed to include the PA Warrant Shares for resale in the registration statement of which this prospectus forms a part, along with the Shares, the Series Warrant Shares and the Series B Warrant Shares.

Selling Stockholders Table

The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders. The table below sets forth information as of the date of this prospectus, to our knowledge, about the beneficial ownership of our common stock by the selling stockholders both before and immediately after this offering. Because the selling stockholders may sell, transfer, or otherwise dispose of all, some, or none of their shares of common stock, we cannot determine the number of such shares that will be sold, transferred or otherwise disposed of by the selling stockholders, or the amount or percentage of shares of our common stock that will be held by the selling stockholders upon termination of any particular offering. See “Plan of Distribution.” For purposes of the table below, we assume that the selling stockholders will sell all of their shares of common stock.

Name	Shares of Common Stock Beneficially Owned Before Completion of the Offering (1)		Sum of Number of Common Stock Offered Hereby (2)	Shares of Common Stock Beneficially Owned After Completion of the Offering (3)	
	Sum of Number	Percentage		Sum of Number	Percentage
Carlo Alberici (4)	44,400	*	44,400	0	*
James R. Aldridge (4)	71,040	*	71,040	0	*
Jonathan E. Ansbacher (4)	26,640	*	26,640	0	*
Peter Appel (4)	1,776,190	7.4%	1,776,190	0	*

Thomas Wiseman Archer (4)	133,210	*	133,210	0	*
Puneet S. Arora (4)	62,160	*	62,160	0	*
Joseph C. Atkinson (4)	88,800	*	88,800	0	*
Ballington Living Trust DTD 8-5-14 (4)(8)	44,400	*	44,400	0	*
Bret Harvey Balonick (4)	13,320	*	13,320	0	*
Stealth Funding Corp (4)(9)	26,640	*	26,640	0	*
Steven Baum (4)	88,800	*	88,800	0	*
Keith A. Belote (4)	26,640	*	26,640	0	*
Chase Lankford Bice	26,640	*	26,640	0	*
Charles Franklin Black & Virginia Gibson Black JT Ent (4)	26,640	*	26,640	0	*
Keith E Bodnar (4)	26,640	*	26,640	0	*
Kevin M. Borkowski (4)	17,760	*	17,760	0	*
Mark W. Boyer (4)	88,800	*	88,800	0	*
Jeffrey Ronald Boyle (4)	62,160	*	62,160	0	*
John M. Brady (4)	44,400	*	44,400	0	*
Joseph Michael Buonaiuto (4)	44,400	*	44,400	0	*
Ryan D. Burdeno & Susan M. Gore JTWROS (4)	26,640	*	26,640	0	*
Margaret Burke (4)	53,280	*	53,280	0	*
Robert J. Calabro & Jennifer D. Calabro (4)	35,520	*	35,520	0	*
Timothy L. Carpenter & Julie L. Carpenter JTWROS (4)	88,800	*	88,800	0	*
Steven & Kristin Chapin Family Trust DTD 3-10-2015 (4)(10)	355,230	1.5%	355,230	0	*
Dennis L. Chesley (4)	88,800	*	88,800	0	*
Charles Christensen (4)	62,160	*	62,160	0	*
Ronald J. Ciasulli (4)	124,330	*	124,330	0	*
Kieran Claffey (4)	88,800	*	88,800	0	*
Jason Clarke Conine (4)	26,640	*	26,640	0	*
Blue Earth Fund Limited Partnership (4)(11)	177,610	*	177,610	0	*
Charles Tyson Cornell (4)	88,800	*	88,800	0	*
Patrick Courtney & Amber Mariarty JTWROS (4)	35,520	*	35,520	0	*
James J. Damato (4)	26,640	*	26,640	0	*
Louis A. Defalco Trust DTD 5-1-2017 (4)(12)	88,800	*	88,800	0	*
Mario Dell'Aera (4)	133,210	*	133,210	0	*
Mark R. Demich (4)	35,520	*	35,520	0	*
Mark C. Dennon (4)	44,400	*	44,400	0	*
Marjorie Lynn Dhunjishah (4)	88,800	*	88,800	0	*
Daniel DiFilippo (4)	35,520	*	35,520	0	*
Christopher Edward DiPetrillo (4)	26,640	*	26,640	0	*
Francis Dominique & Majella Dominique JTWROS (4)	26,640	*	26,640	0	*
John F. Dougherty III (4)	35,520	*	35,520	0	*
Joel Ebu (4)	168,730	*	168,730	0	*
Paul G. Elie (4)	133,210	*	133,210	0	*
Robert Clinton Elliott (4)	53,280	*	53,280	0	*
Miles E. Everson (4)	62,160	*	62,160	0	*
Michael Fahey (4)	222,020	*	222,020	0	*
Targeted Investments 2028 No 2 LLC (4)(13)	35,520	*	35,520	0	*
Keith Fleischmann (4)	44,400	*	44,400	0	*
Gerald M. Flynn & Lynn A. Flynn JTWROS (4)	266,420	1.1%	266,420	0	*
Martin Thomas Foley (4)	44,400	*	44,400	0	*
Paul P. Frank III & Colleen B. Frank Joint Tenants by Entirety (4)	44,400	*	44,400	0	*
Jay Charter Garrels & Alison Lee Furman JTWROS (4)	26,640	*	26,640	0	*
Brian Mark Geiger (4)	26,640	*	26,640	0	*
Ergun Genc (4)	177,610	*	177,610	0	*
Kevin A. Healy (4)	133,210	*	133,210	0	*

Brian L. Heckler (4)	35,520	*	35,520	0	*
Michael A. Herman (4)	35,520	*	35,520	0	*
Scott Frederic Hesse & Patricia Lynn Hesse JTWROS (4)	44,400	*	44,400	0	*
Dennis D. Howarter & Pamela J. Howarter JTWROS (4)	88,800	*	88,800	0	*
James M. Huber Trust DTD 1-28-2020 James M. Huber TTEE (4)(14)	44,400	*	44,400	0	*
Eric D. Janson & Ruth Ann Janson JT TEN COM (4)	133,210	*	133,210	0	*
Mohamed Kadher Kande (4)	44,400	*	44,400	0	*
David A. Katz (4)	106,570	*	106,570	0	*
Robert Richard Keehan (4)	88,800	*	88,800	0	*
Frederick M. Kelso (4)	53,280	*	53,280	0	*
Robert K. Kimes (4)	62,160	*	62,160	0	*
Casey Carl Kirkpatrick (4)	88,800	*	88,800	0	*
John G. Klinge (4)	44,400	*	44,400	0	*
James M. Koch (4)	44,400	*	44,400	0	*
James P. Kolar (4)	88,800	*	88,800	0	*
John C. Koppin (4)	35,520	*	35,520	0	*
Todd David Kosel (4)	44,400	*	44,400	0	*
Kurtis Krentz (4)	88,800	*	88,800	0	*
Jeffrey E. Kuhlin (4)	26,640	*	26,640	0	*
James C. Leslie (4)	53,280	*	53,280	0	*
Jason Matthew Levin & Rachel Nooromid Levin JTWROS (4)	26,640	*	26,640	0	*
Brian Michael Levy (4)	177,610	*	177,610	0	*
Steven R. Lilley (4)	26,640	*	26,640	0	*
Matthew W. Mabe (4)	26,640	*	26,640	0	*
Adrian Mantini & Jennifer Mantini JTWROS (4)	26,640	*	26,640	0	*
Jedidiah Marshall (4)	26,640	*	26,640	0	*

Todd A. Martin (4)	88,800	*	88,800	0	*
Kyle V. Maryanski (4)	35,520	*	35,520	0	*
Thorne Joseph Brown Matteson (4)	62,160	*	62,160	0	*
Robert B. McCency (4)	88,800	*	88,800	0	*
Jeffery L. Miller & Khristen N. Zar JTWROS (4)	177,610	*	177,610	0	*
James Dale Miller (4)	44,400	*	44,400	0	*
Sokho Moon (4)	44,400	*	44,400	0	*
Jonathon E. Moulden (4)	26,640	*	26,640	0	*
Chad F. Mueller (4)	177,610	*	177,610	0	*
John Nardulli & Cynthia Nardulli JTWROS (4)	44,400	*	44,400	0	*
Stephen H. Nesi (4)	44,400	*	44,400	0	*
James Eric Nicely & Karen B. Nicely JTWROS (4)	26,640	*	26,640	0	*
Michael P. Niland & Jill Kathleen Niland JTWROS (4)	44,400	*	44,400	0	*
Richard Douglas Nix Revoc Trust DTD 4-28-2019 (4)(15)	88,800	*	88,800	0	*
Cornel Leonard Nolte (4)	177,610	*	177,610	0	*
Harvey Beach Club Holdings LLC (4)(16)	44,400	*	44,400	0	*
David B. O'Neill (4)	44,400	*	44,400	0	*
Padinha Management Trust DTD 8-12-2021 (4)(17)	177,610	*	177,610	0	*
Benjamin L. Padnos (4)	177,610	*	177,610	0	*
Robert A. Page (4)	26,640	*	26,640	0	*
Alexandre N. Palma (4)	88,800	*	88,800	0	*
Laurence M. Pfeffer (4)	44,400	*	44,400	0	*
Michael Patrick Pokorski (4)	26,640	*	26,640	0	*
John D. Potter (4)	53,280	*	53,280	0	*
Thomas Puthiyamadam (4)	133,210	*	133,210	0	*
Michael P. Quackenbush Jr. (4)	35,520	*	35,520	0	*
Michael F. Quinlan (4)	26,640	*	26,640	0	*
William Fox Reepmeyer (4)	26,640	*	26,640	0	*
Juan R. Rivero (4)	71,040	*	71,040	0	*
Thomas Michael Rooney (4)	53,280	*	53,280	0	*
Derek Jorge Santana & Samantha Michelle Santana JTWROS (4)	44,400	*	44,400	0	*
MAZ Partners LP ATTN Walter Schenker (4)(18)	53,280	*	53,280	0	*
Jeremy William Schlee (4)	62,160	*	62,160	0	*
Scott Joseph Schueller (4)	71,040	*	71,040	0	*
Donald P. Sesterhen (4)	44,400	*	44,400	0	*
Barrett J. Shipman (4)	35,520	*	35,520	0	*
Marc D. Silverman & Mitra Best Silverman JTWROS (4)	44,400	*	44,400	0	*
Richard Edward Sleigh (4)	44,400	*	44,400	0	*
Thomas Euclid Smith Jr (4)	44,400	*	44,400	0	*
The Snow Family Trust DTD 6-4-2021 (4)(19)	44,400	*	44,400	0	*

Renton Squires & Makiko Imada Family Trust DTD 9/19/2002 (4)(20)	26,640	*	26,640	0	*
John W. Stadler (4)	88,800	*	88,800	0	*
Gary S. Sterbinsky (4)	26,640	*	26,640	0	*
Kevin D. Sullivan (4)	44,400	*	44,400	0	*
James Douglas Summa (4)	35,520	*	35,520	0	*
Pierre Alain Nicholas P Sur (4)	26,640	*	26,640	0	*
Robert B. Taylor (4)	44,400	*	44,400	0	*
Oscar Teunissen (4)	97,690	*	97,690	0	*
Ironwood Assets LLC (4)(21)	177,610	*	177,610	0	*
Chetan R. Vagholkar (4)	177,610	*	177,610	0	*
Candlestick Lane Investments LP (4)(22)	133,210	*	133,210	0	*
Timothy S. Vitale (4)	44,400	*	44,400	0	*
Wells/Koehler Family Trust DTD 12-27-2016 (4)(23)	88,800	*	88,800	0	*
Trust of the 2014 Wen Family Trust DTD 9-4-2014 (4)(24)	62,160	*	62,160	0	*
Colin E. Wittmer (4)	62,160	*	62,160	0	*
Mikel S. Woods (4)	26,640	*	26,640	0	*
Theodore Robert Young (4)	88,800	*	88,800	0	*
Mohibullah Yousufani (4)	44,400	*	44,400	0	*
Eugene Zaino (4)	88,800	*	88,800	0	*
Jeffrey E. Zaleski (4)	44,400	*	44,400	0	*
Stephen V. Zawoyski (4)	26,640	*	26,640	0	*
Jonathan H Zinno (4)	26,640	*	26,640	0	*
David B Martin Jr. (4)	239,780	1.0%	239,780	0	*
William K. Schmitt (4)	26,640	*	26,640	0	*
Magnus Almquist (4)	26,640	*	26,640	0	*
Keith Guenther (4)	177,610	*	177,610	0	*
Jacobson Sorensen Rev Trust (4)(25)	159,850	*	159,850	0	*
Kevin Wu (4)	222,020	*	222,020	0	*
Rocco Brescia (4)	35,520	*	35,520	0	*
Mohan Maheswaran (4)	26,640	*	26,640	0	*
Stephen Kupferberg (4)	26,640	*	26,640	0	*
Charles E Benges (4)	26,640	*	26,640	0	*
Mac Trust LLC (4)(26)	88,800	*	88,800	0	*
Ronald V Scoleri (4)	88,800	*	88,800	0	*
Mark Allen Ropchock (4)	53,280	*	53,280	0	*
Steven Wietsma (4)	44,400	*	44,400	0	*
Michael Burrow (4)	62,160	*	62,160	0	*
Specialty & Ball Valve (4)(27)	26,640	*	26,640	0	*

Gregg Aratin (4)	26,640	*	26,640	0	*
David Chelf (4)	26,640	*	26,640	0	*
James Ritman (4)	30,190	*	30,190	0	*
Andrew Schwartzberg (5)	5,328,750	22.2%	5,328,750	0	*
ADAR1 (4)(28)	888,100	3.7%	888,100	0	*
Warberg WF XI LP (4)(28)	200,000	*	200,000	0	*
Raj Maheshwari (Charlestown Capital Advisors)(4)	177,620	*	177,620	0	*
Tony Chou (4)	35,520	*	35,520	0	*
Renny Kuruvilla (6)	242,199	*	242,199	0	*
Alden Carrere (7)	18,174	*	18,174	0	*
Andrew Gallion (7)	10,400	*	10,400	0	*
Chad Champion (7)	87,054	*	87,054	0	*
	20,000	*	20,000	0	*
Charles Wanyama (7)					
Christopher Villa (7)	12,000	*	12,000	0	*
Gina Buddie (7)	3,174	*	3,174	0	*
Guy Amico (7)	15,871	*	15,871	0	*
Joseph Glodek (7)	95,902	*	95,902	0	*
Linda Acri (7)	8,000	*	8,000	0	*
Michael Intermoscia (7)	8,500	*	8,500	0	*
Newbridge Securities Corporation (7)(30)	15,871	*	15,871	0	*
Richard Libretti (7)	95,901	*	95,901	0	*
Robert Spitler (7)	6,348	*	6,348	0	*
Salvatore Esposito (7)	66,270	*	66,270	0	*
Scott Goldstein (7)	15,871	*	15,871	0	*
Thomas Casolaro (7)	6,348	*	6,348	0	*
Total Selling Stockholders			20,482,153		

* Less than 1%.

- (1) Applicable percentages based on 23,949,830 shares of common stock outstanding as of the date of this prospectus. Beneficial Ownership prior to this offering includes any share options either vested or which will vest within 60 days of the filing of this registration statement, and any common stock warrants exercisable within 60 days of the filing of this registration statement.
- (2) Consists of Shares and Investor Warrant Shares or PA Warrant Shares (as the case may be), with respect to each selling stockholder, in connection with the April 2024 Private Placement.
- (3) Assumes full exercise of all Investor Warrants or PA Warrants (as the case may be) by each selling stockholder and the resale or other disposition of all Shares and all Investor Warrant Shares or PA Warrant Shares (as the case may be) by each such selling stockholder.
- (4) 40% of the shares of common stock being offered for sale by such selling stockholder are issuable pursuant to a Series A Warrant, exercisable at an exercise price of \$1.22 per share, and 20% of the shares of common stock being offered for sale by such selling stockholder are issuable pursuant to a Series B Warrant, which is exercisable at an exercise price of \$1.22 per share. The remaining 40% of the shares being offered are shares of common stock purchased in the April 2024 Private Placement.
- (5) The shares of common stock being offered by Mr. Schwartzberg includes (i) 1,180,000 shares of common stock, (ii) 951,500 shares issuable upon exercise of a Pre-Funded Warrant, exercisable at an exercise price of \$0.0001 per share, and (ii) 3,197,250 shares issuable upon exercise of Series A Warrants and Series B Warrants, each at an exercise price of \$1.22 per share.
- (6) The shares of common stock being offered for sale by Mr. Kuruvilla include (i) 10,656 shares of common stock purchased in the April 2024 Private Placement, (ii) 15,984 shares issuable upon exercise of Series A Warrants and Series B Warrants, each, exercisable at an exercise price of \$1.22 per share and (ii) 215,559 shares exercisable upon exercise of PA Warrants, which are immediately exercisable at an exercise price of \$1.69 per share. Mr. Kuruvilla is associated with Newbridge Securities Corporation.
- (7) The shares of common stock being offered for sale by such selling stockholder are issuable pursuant to a PA Warrant, which is immediately exercisable at an exercise price of \$1.69 per share. The individuals noted are associated with Newbridge Securities Corporation, the placement agent for the April 2024 Private Placement.
- (8) Edward WS Ballington has voting and dispositive power over the securities held by this selling stockholder.
- (9) Michael Barone has voting and dispositive power over the securities held by this selling stockholder.
- (10) Steven Chapin has voting and dispositive power over the securities held by this selling stockholder.
- (11) Brett Conrad has voting and dispositive power over the securities held by this selling stockholder.
- (12) Louis A. Defalco has voting and dispositive power over the securities held by this selling stockholder.
- (13) Christopher Finnerty has voting and dispositive power over the securities held by this selling stockholder.
- (14) James M. Huber has voting and dispositive power over the securities held by this selling stockholder.
- (15) Richard Douglas Nix has voting and dispositive power over the securities held by this selling stockholder.
- (16) Brett Oliver has voting and dispositive power over the securities held by this selling stockholder.
- (17) Henry Padinha has voting and dispositive power over the securities held by this selling stockholder.
- (18) Walter Schenker has voting and dispositive power over the securities held by this selling stockholder.
- (19) Michael Snow has voting and dispositive power over the securities held by this selling stockholder.
- (20) Renton Squires has voting and dispositive power over the securities held by this selling stockholder.
- (21) Eric K. Thompson has voting and dispositive power over the securities held by this selling stockholder.
- (22) Daniel Verret has voting and dispositive power over the securities held by this selling stockholder.
- (23) Jason P. Wells has voting and dispositive power over the securities held by this selling stockholder.
- (24) Don Tzei Wen has voting and dispositive power over the securities held by this selling stockholder.
- (25) Michael Jacobson has voting and dispositive power over the securities held by this selling stockholder.
- (26) Dennis Michael Mckenna has voting and dispositive power over the securities held by this selling stockholder.
- (27) Harry Buehrle has voting and dispositive power over the securities held by this selling stockholder.
- (28) Daniel Schneeberger has voting and dispositive power over the securities held by this selling stockholder.
- (29) Daniel Warsh has voting and dispositive power over the securities held by this selling stockholder.
- (30) Robert P. Spitler has voting and dispositive power over the securities held by this selling stockholder.

PLAN OF DISTRIBUTION

We are registering the Selling Stockholder Shares on behalf of the selling stockholders to permit the resale of such shares by the selling stockholders from time to time after the date of this prospectus. The Selling Stockholder Shares were purchased or are acquirable by the selling stockholders, who participated in the January 2024 Private

Placement. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.

The selling stockholders, which may include donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholders as a gift, pledge, partnership distribution or other transfer, may sell all or a portion of the shares of common stock beneficially owned by them and offered hereby from time to time on any stock exchange, market or trading facility on which the shares are traded or in private transactions.

A selling stockholder may use any one or more of the following methods when disposing of shares or interests therein:

- ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
- block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
- purchases by a broker-dealer as principal and resale by the broker-dealer for its own account;
- an exchange distribution in accordance with the rules of the applicable exchange;
- privately negotiated transactions;
- through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
- through agreements between broker-dealers and the selling stockholders to sell a specified number of such shares at a stipulated price per share;
- a combination of any such methods of sale; and
- any other method permitted by applicable law.

The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the pledgees, transferees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, as permitted by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus; provided that they meet the criteria and conform to the requirements of those provisions.

11

In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into options or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to each such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. The selling stockholders reserve the right to accept and, together with its agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering.

The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. If the selling stockholders is an “underwriter” within the meaning of Section 2(11) of the Securities Act, it will be subject to the prospectus delivery requirements of the Securities Act.

To the extent required, the shares of our common stock to be sold, the name of the selling stockholder, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.

If underwriters are used in the sale, the shares of common stock will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. In connection with any such underwritten sale of shares of common stock, underwriters may receive compensation from the selling stockholder, for whom they may act as agents, in the form of discounts, concessions or commissions. If the selling stockholder uses an underwriter or underwriters to effectuate the sale of shares of common stock, we and/or it will execute an underwriting agreement with those underwriters at the time of sale of those shares of common stock.

To the extent required by law, the names of the underwriters will be set forth in a prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes the prospectus supplement and the accompanying prospectus used by the underwriters to sell those securities. The obligations of the underwriters to purchase those shares of common stock will be subject to certain conditions precedent, and unless otherwise specified in a prospectus supplement, the underwriters will be obligated to purchase all the shares of common stock offered by such prospectus supplement if any of such shares of common stock are purchased. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time.

The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

Listing

Our common stock is listed on The Nasdaq Capital Market under the trading symbol “RNXT.”

12

LEGAL MATTERS

The validity of the issuance of the securities offered hereby was passed upon for us by Ellenoff Grossman & Schole LLP, New York, New York.

EXPERTS

The financial statements of RenovoRx, Inc. as of and for the year ended December 31, 2023 and 2022 incorporated by reference in this registration statement, have been audited by Baker Tilly US, LLP, an independent registered public accounting firm, as set forth in their report thereon incorporated by reference in this registration statement, in reliance upon such report and upon the authority of said firm as experts in accounting and auditing. The above referenced report on the financial statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-3, of which this prospectus is a part, under the Securities Act, to register the shares of common stock offered by this prospectus. However, this prospectus does not contain all of the information contained in the Registration Statement. We have omitted from this prospectus some parts of the Registration Statement as permitted by the rules and regulations of the SEC. Statements in this prospectus concerning any document we have filed as an exhibit to the Registration Statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified in their entirety by reference to these filings. In addition, we file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act, can also be accessed free of charge from our website at <http://www.adnas.com>. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information contained on our website is not part of this prospectus.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC's rules allow us to "incorporate by reference" information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement.

This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC:

- our Annual Report on [Form 10-K](#) for the year ended December 31, 2023, filed with the SEC on April 1, 2024;
- our Current Reports on Form 8-K, which were filed with the SEC on [January 2, 2024](#), [January 29, 2024](#), [February 9, 2024](#), [February 23, 2024](#), [March 14, 2024](#), [April 9, 2024](#), [April 15, 2024](#), [April 16, 2024](#), [April 18, 2024](#), and [May 3, 2024](#); and
- the description of our common stock set forth in our registration statement on [Form 8-A](#), filed with the SEC on August 11, 2021, including any amendments thereto or reports filed for the purposes of updating this description.

Any documents we file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, as well as subsequent to the effectiveness of the registration statement and prior to the termination of the offering of our securities to which this prospectus relates, will automatically be deemed to be incorporated by reference into this prospectus and to be part hereof from the date of filing those documents. We are not, however, incorporating by reference any documents or portions thereof that are not deemed "filed" with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.

You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number:

RenovoRx, Inc.
Attn: Investor Relations
4546 El Camino Real, Suite B1
Los Altos, California 94022
650-284-4433

The information accessible through any website referred to in this prospectus or any document incorporated herein is not, and should not be deemed to be, a part of this prospectus.

The logo for RenovoRx, featuring the word "RENOVO" in a bold, blue, sans-serif font, followed by a vertical bar and the letters "RX" in a lighter blue, sans-serif font.

6,960,864 Shares of Common Stock
951,500 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrant
7,912,364 Shares of Common Stock Issuable Upon Exercise of Series A Warrants
3,956,182 Shares of Common Stock Issuable Upon Exercise of Series B Warrants
701,243 Shares of Common Stock Issuable Upon Exercise of Placement Agent Warrants

Offered by the Selling Stockholders

PROSPECTUS

May 10, 2024
